The period in brief – financial summary for the first quarter 2024
- Net sales amounted to
SEK 0 million (SEK 0 million ) - R&D expenses amounted to
SEK 11,4 million (SEK 15,2 million ) - Operating loss for the quarter amounted to SEK –13,4 million (
SEK -17,2 million ) - Loss after financial items for the quarter amounted to SEK –13,0 million (
SEK -17,5 million ) - Basic and diluted earnings per share for the quarter amounted to SEK –0,13 (SEK -0,22)
- Cash flow from operating activities for the quarter amounted to SEK –14,7 million (
SEK -19,0 million ) - Equity as of
March 31, 2024 amounted toSEK 93,9 million (SEK 89,4 million ) orSEK 0,77 (SEK 1,12 ) per share - The equity ratio on
31 March 2024 was 76 percent (85 percent) - Cash and cash equivalents on
March 31, 2024 amounted toSEK 31,0 million (SEK 76,1 million )
Significant events during the first quarter 2024
Kancera reported that the company had entered into a license agreement with theUniversity of Newcastle , through which the company retains the exclusive rights to the results and patents from the FRACTAL study.Kancera reported that the company’s updated protocol for the Kandova study has been approved inSweden ,Norway andDenmark .Kancera reported its intention to carry out a rights issue totalingSEK 121,9 million .Kancera reported the outcome of the rights issue; ApproximatelySEK 73,0 million was raised before issue costs, which corresponded to approximately 60% of the total rights issue.
Important events after the end of the period
Kancera has reported positive overall results from the phase I study with KAND145Kancera has reported thatRobert Edfors has been appointed as Chief Scientific Officer and Senior Vice President Clinical Development as fromSeptember 1, 2024 , and further thatMaria Sahlberg has been appointed Vice President Regulatory Affairs & Compliance andJohan Schultz has been appointed Vice President Research & Development Operations.
About
For further information
Please refer the presentation of the 2024 Q1 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/
or contact:
ir@kancera.com or phone: +46 (0)8-5012 60 80
© Modular Finance, source